CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered for significantly extended plasma half-life. The incorporation of the Drug Affinity Complex technology enables covalent binding to serum albumin following administration, prolonging the peptide’s active duration from minutes to several days compared to native GHRH. This mechanism results in sustained stimulation of the pituitary gland’s somatotroph cells, promoting continuous pulsatile release of endogenous growth hormone (GH) and consequently elevating insulin-like growth factor 1 (IGF-1) levels.
In research settings, CJC-1295 with DAC has been studied extensively in the context of growth hormone deficiency models, metabolic regulation, and body composition research. Its extended half-life makes it a valuable tool for investigating chronic GH axis stimulation without the need for frequent dosing intervals.
Specifications: Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆; Molecular Weight: 3647.1 g/mol; Purity: >98% by HPLC; CAS Number: 863288-34-0; Form: Lyophilised Powder. Each vial contains 5mg of peptide. Store lyophilised peptide at -20°C, protected from light and moisture. Once reconstituted, store at 4°C and use within 14 days.
Molecular Formula
C₁₆₅H₂₆₉N₄₇O₄₆
Molecular Weight
3647.1 g/mol
Purity
>98%
CAS Number
863288-34-0
Form
Lyophilised Powder
Research Applications
Growth hormone axis research, Metabolic regulation studies, Body composition research, GH deficiency models, IGF-1 pathway investigation, Pituitary function research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.